[1] RAZIN S,YOGEV D,NAOT Y.Molecular biology and pathogenicity of mycoplasmas[J].Microbiology and Molecular Biology Reviews,1998,62(4):1094-1156. [2] ZHAO G,LU D K,LI M,et al.Gene editing tools for mycoplasmas:references and future directions for efficient genome manipulation[J].Frontiers in Microbiology,2023,14:1191812. [3] BROTO A,GASPARI E,MIRAVET-VERDE S,et al.A genetic toolkit and gene switches to limit Mycoplasma growth for biosafety applications[J].Nature Communications,2022,13(1):1910. [4] MIZUTANI M,GLASS J I,FUKATSU T,et al.Robust and highly efficient transformation method for a minimal Mycoplasma cell[J].Journal of Bacteriology,2025,207(3):e00415-e00424. [5] FRANKE A E,CLEWELL D B.Evidence for a chromosome-borne resistance transposon (Tn916) in Streptococcus faecalis that is capable of "conjugal" transfer in the absence of a conjugative plasmid[J].Journal of Bacteriology,1981,145(1):494-502. [6] KENRI T.Genetic manipulation of Mycoplasma pneumoniae[M]//MINAMINO T,MIYATA M,NAMBA K.Methods in Molecular Biology. New York:Humana Press,2023:347-357. [7] BONNEFOIS T,VERNEREY M S,RODRIGUES V,et al.Development of fluorescence expression tools to study host-Mycoplasma interactions and validation in two distant Mycoplasma clades[J].Journal of Biotechnology,2016,236:35-44. [8] WANG Y,YI L,ZHANG F Q,et al.Identification of genes involved in Mycoplasma gallisepticum biofilm formation using mini-Tn4001-SGM transposon mutagenesis[J].Veterinary Microbiology,2017,198:17-22. [9] LYON B R,MAY J W,SKURRAY R A.Tn4001:a gentamicin and kanamycin resistance transposon in Staphylococcus aureus[J].Molecular and General Genetics MGG,1984,193(3):554-556. [10] CHEN H J,ZHAO C M,SHEN X Y,et al.Construction of mini-Tn4001 transposon vector for Mycoplasma gallisepticum[J].Science China Life Sciences,2010,53(11):1340-1345. [11] RUBIN E J,AKERLEY B J,NOVIK V N,et al.In vivo transposition of mariner-based elements in enteric bacteria and mycobacteria[J].Proceedings of the National Academy of Sciences of the United States of America,1999,96(4):1645-1650. [12] MAGLENNON G A,COOK B S,DEENEY A S,et al.Transposon mutagenesis in Mycoplasma hyopneumoniae using a novel mariner-based system for generating random mutations[J].Veterinary Research,2013,44(1):124. [13] TRUEEB B S,GERBER S,MAES D,et al.Tn-sequencing of Mycoplasma hyopneumoniae and Mycoplasma hyorhinis mutant libraries reveals non-essential genes of porcine mycoplasmas differing in pathogenicity[J].Veterinary Research,2019,50:55. [14] MAHDIZADEH S,SANSOM F M,LEE S W,et al.Targeted mutagenesis of Mycoplasma gallisepticum using its endogenous CRISPR/Cas system[J].Veterinary Microbiology,2020,250:108868. [15] KLOSE S M,WAWEGAMA N,SANSOM F M,et al.Efficient disruption of the function of the mnuA nuclease gene using the endogenous CRISPR/Cas system in Mycoplasma gallisepticum[J].Veterinary Microbiology,2022,269:109436. [16] EVSYUTINA D V,FISUNOV G Y,POBEGUTS O V,et al.Gene silencing through CRISPR interference in mycoplasmas[J].Microorganisms,2022,10(6):1159. [17] MARISCAL A M,KAKIZAWA S,HSU J Y,et al.Tuning gene activity by inducible and targeted regulation of gene expression in minimal bacterial cells[J].ACS Synthetic Biology,2018,7(6):1538-1552. [18] IPOUTCHA T,RIDEAU F,GOURGUES G,et al.Genome editing of veterinary relevant mycoplasmas using a CRISPR-cas base editor system[J].Applied and Environmental Microbiology,2022,88(17):e00996-e00922. [19] PIÑERO-LAMBEA C,GARCIA-RAMALLO E,MIRAVET-VERDE S,et al. SURE editing:combining oligo-recombineering and programmable insertion/deletion of selection markers to efficiently edit the Mycoplasma pneumoniae genome[J].Nucleic Acids Research,2022,50(22):e127. [20] IPOUTCHA T,GOURGUES G,LARTIGUE C,et al.Genome engineering in Mycoplasma gallisepticum using exogenous recombination systems[J].ACS Synthetic Biology,2022,11(3):1060-1067. [21] PIÑERO-LAMBEA C,GARCIA-RAMALLO E,MARTINEZ S,et al. Mycoplasma pneumoniae genome editing based on oligo recombineering and Cas9-mediated counterselection[J].ACS Synthetic Biology,2020,9(7):1693-1704. [22] GAJ T,SIRK S J,SHUI S L,et al.Genome-editing technologies:principles and applications[J].Cold Spring Harbor Perspectives in Biology,2016,8(12):a023754. [23] HU J,YE Y Y,CHEN X X,et al.Insight into the pathogenic mechanism of Mycoplasma pneumoniae[J].Current Microbiology,2023,80:14. [24] TSENG C W,CHIU C J,KANCI A,et al.Safety and efficacy of a Mycoplasma gallisepticum oppD knockout mutant as a vaccine candidate[J].Vaccine,2017,35(45):6248-6253. [25] TALENTON V,BABY V,GOURGUES G,et al.Genome engineering of the fast-growing Mycoplasma feriruminatoris toward a live vaccine chassis[J].ACS Synthetic Biology,2022,11(5):1919-1930. [26] HUTCHISON C A,PETERSON S N,GILL S R,et al.Global transposon mutagenesis and a minimal Mycoplasma genome[J].Science,1999,286(5447):2165-2169. [27] MONTERO-BLAY A,MIRAVET-VERDE S,LLUCH-SENAR M,et al.SynMyco transposon:engineering transposon vectors for efficient transformation of minimal genomes[J].DNA Research,2019,26(4):327-339. [28] RAMOS E I,VEERAPANDIAN R,DAS K,et al.Pathogenic mycoplasmas of humans regulate the long noncoding RNAs in epithelial cells[J].Non-coding RNA Research,2023,8(3):282-293. [29] 王永明. 猪圆环病毒病(2型)、猪支原体肺炎基因工程二联灭活疫苗的研究与开发[D].兰州:甘肃农业大学,2022. [30] LI G,ZHOU J,GAO N N,et al.Establishment of a rapid detection method for Mycoplasma pneumoniae based on RPA-CRISPR-Cas12a technology[J].Clinica Chimica Acta,2025,564:119906. [31] ZHOU J,XIAO F,FU J,et al.Rapid,ultrasensitive and highly specific diagnosis of Mycoplasma pneumoniae by a CRISPR-based detection platform[J].Frontiers in Cellular and Infection Microbiology,2023,13:1147142. [32] HUTCHISON C A,CHUANG R Y,NOSKOV V N,et al. Design and synthesis of a minimal bacterial genome[J].Science,2016,351(6280):aad6253. [33] ISHAG H Z A,LIU M J,YANG R S,et al. A replicating plasmid-based vector for GFP expression in Mycoplasma hyopneumoniae[J].Genetics and Molecular Research,2016,15(2):gmr.15027896. [34] RUIZ E,TALENTON V,DUBRANA M P,et al.CReasPy-cloning:a method for simultaneous cloning and engineering of megabase-sized genomes in yeast using the CRISPR-Cas9 system[J].ACS Synthetic Biology,2019,8(11):2547-2557. [35] ARROYO-OLARTE R D,BRAVO RODRÍGUEZ R,MORALES-RÍOS E. Genome editing in bacteria:CRISPR-cas and beyond[J].Microorganisms,2021,9(4):844. [36] FUS-KUJAWA A,PRUS P,BAJDAK-RUSINEK K,et al.An overview of methods and tools for transfection of eukaryotic cells in vitro[J].Frontiers in Bioengineering and Biotechnology,2021,9:701031. [37] RINGGAARD L,MELANDER F,ELIASEN R,et al. Tumor repolarization by an advanced liposomal drug delivery system provides a potent new approach for chemo-immunotherapy[J].Science Advances,2020,6(36):eaba5628. [38] SAYSON S G,ASHBAUGH A,BALIER L C, et al.Extracellular vesicle-mediated delivery of genetic material for transformation and CRISPR/Cas9-based gene editing in Pneumocystis murina[J].mBio,2025,16(11):e01825. [39] ASENCIO C,HERVÉ P,MORAND P,et al.Streptococcus pyogenes Cas9 ribonucleoprotein delivery for efficient,rapid and marker-free gene editing in Trypanosoma and Leishmania[J].Molecular Microbiology,2024,121(6):1079-1094. [40] SOFRAS D,CAROLUS H,SUBOTIĆ A,et al.A systematic comparison of CRISPR-Cas9 allele editing in Candida auris demonstrates unreliable cassette integration and effective episomal plasmid-based editing[J].Scientific Reports,2025,15:35105. [41] TORRES-PUIG S,CRESPO-POMAR S,AKARSU H,et al.Functional surface expression of immunoglobulin cleavage systems in a candidate Mycoplasma vaccine chassis[J].Communications Biology,2024,7:779. |